PA32540 Safe for Patients at Risk of Aspirin-Linked Upper GI Events

This article originally appeared here.
Share this content:
PA32540 Safe for Patients at Risk of Aspirin-Linked Upper GI Events
PA32540 Safe for Patients at Risk of Aspirin-Linked Upper GI Events

TUESDAY, March 15, 2016 (HealthDay News) -- For subjects at risk of aspirin-associated upper gastrointestinal (UGI) events, long-term PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) appears to be safe, according to a study published in the April issue of Cardiovascular Therapeutics.

Jay L. Goldstein, M.D., from the NorthShore University HealthSystem in Evanston, Ill., and colleagues conducted a 12-month, open-label, multicenter phase 3 trial to examine the long-term cardiovascular and gastrointestinal safety of PA32540. Subjects who were taking aspirin 325 mg daily for three or more months for secondary cardiovascular disease prevention and were at risk for UGI events were enrolled. Participants received PA32540 once daily for up to 12 months; assessments were conducted at baseline and at months one, six, and 12.

The researchers found that the safety population included 379 subjects, of whom 76 percent were on PA32540 for 348 or more days (12-month completers). In 13.5 percent of patients, adverse events (AEs) caused study withdrawal, most often gastroesophageal reflux disease (1.1 percent). Seventy-six percent of the safety population and 73 percent of 12-month completers had treatment-emergent AEs (11 and 8 percent, respectively, were treatment related). Dyspepsia was the most common treatment-related AE (2 percent).

"Long-term treatment with PA32540 once daily for up to 12 months in subjects at risk for aspirin-associated UGI events is not associated with any new or unexpected safety events," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including POZEN Inc., which funded the study.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Generic EpiPen

FDA Approves First Generic EpiPen

Approval will address both rising costs and shortages of epinephrine

Report Details Corneal Infection Tied to Sleeping in Contacts

Report Details Corneal Infection Tied to Sleeping in ...

Six patients reported sleeping in lenses on regular basis; most had vision loss, permanent damage

Honey May Protect Children Who Swallow Button Batteries

Honey May Protect Children Who Swallow Button Batteries

Honey and Carafate appear to rapidly protect against batteries' caustic effects

is free, fast, and customized just for you!




Already a member?

Sign In Now »